Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction

CONTEXT: Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and improves left ventricular (LV) function. OBJECTIVE: To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in patients with STEMI. DESIGN, SETTING, AND PATIENTS: A prospective, randomized, double-blind, placebo-controlled trial with a dose-escalation safety phase and a single dose (60, 000 U of epoetin alfa) efficacy phase; the Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction (REVEAL) trial was conducted at 28 US sites between October 2006 and February 2010, and included 222 patients with STEMI who underwent successful percutaneous coronary intervention (PCI) as a primary or rescue reperfusion strategy. INTERVENTION: Participants were randomly assigned to treatment with intravenous epoetin alfa or matching saline placebo administered within 4 hours of reperfusion. MAIN OUTCOME MEASURE: Infarct size, expressed as percentage of LV mass, assessed by cardiac magnetic resonance (CMR) imaging performed 2 to 6 days after study medication administration (first CMR) and again 12 ± 2 weeks later (second CMR). RESULTS: In the efficacy cohort, the infarct size did not differ between groups on either the first CMR scan (n = 136; 15. 8% LV mass 95% confidence interval CI, 13. 3-18. 2% LV mass for the epoetin alfa group vs 15. 0% LV mass 95% CI, 12. 6-17. 3% LV mass for the placebo group; P =. 67) or on the second CMR scan (n = 124; 10. 6% LV mass 95% CI, 8. 4-12. 8% LV mass vs 10. 4% LV mass 95% CI, 8. 5-12. 3% LV mass, respectively; P =. 89). In a prespecified analysis of patients aged 70 years or older (n = 21), the mean infarct size within the first week (first CMR) was larger in the epoetin alfa group (19. 9% LV mass; 95% CI, 14. 0-25. 7% LV mass) than in the placebo group (11. 7% LV mass; 95% CI, 7. 2-16. 1% LV mass) (P =. 03). In the safety cohort, of the 125 patients who received epoetin alfa, the composite outcome of death, MI, stroke, or stent thrombosis occurred in 5 (4. 0%; 95% CI, 1. 31%-9. 09%) but in none of the 97 who received placebo (P =. 04). CONCLUSIONS: In patients with STEMI who had successful reperfusion with primary or rescue PCI, a single intravenous bolus of epoetin alfa within 4 hours of PCI did not reduce infarct size and was associated with higher rates of adverse cardiovascular events. Subgroup analyses raised concerns about an increase in infarct size among older patients. TRIAL REGISTRATION: clinicaltrials. gov Identifier: NCT00378352.